IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study

Jennifer M. T. A. Meessen1, Giulia Cesaroni2, Gian F. Mureddu3, Alessandro Boccanelli4, Ursula-Henrike Wienhues-Thelen2, Peter Kastner5, Luisa Ojeda-Fernandez1, Deborah Novelli1, Gianfranco Bazzoni6, Maurizio Mangiavacchi7, Nera Agabiti2, Serge Masson8, Lidia Staszewsky1, Roberto Latini1* and on behalf of the PREDICTOR Investigators

Abstract

Background: Little is known about the clinical value of Insulin-like growth factor-binding protein-7 (IGFBP7), a cellular senescence marker, in an elderly general population with multiple co-morbidities and high prevalence of asymptomatic cardiovascular ventricular dysfunction. Inflammation and fibrosis are hallmarks of cardiac aging and remodeling. Therefore, we assessed the clinical performance of IGFBP7 and two other biomarkers reflecting these pathogenic pathways, the growth differentiation factor-15 (GFD-15) and amino-terminal propeptide of type I procollagen (P1NP), for their association with cardiac phenotypes and outcomes in the PREDICTOR study.

Methods: 2001 community-dwelling subjects aged 65–84 years who had undergone centrally-read echocardiography, were selected through administrative registries. Atrial fibrillation (AF) and 4 echocardiographic patterns were assessed: E/e’ (> 8), enlarged left atrial area, left ventricular hypertrophy (LVH) and reduced midwall circumference shortening (MFS). All-cause and cardiovascular mortality and hospitalization were recorded over a median follow-up of 10.6 years.

Results: IGFBP7 and GDF-15, but not P1NP, were independently associated with prevalent AF and echocardiographic variables after adjusting for age and sex. After adjustment for clinical risk factors and cardiac patterns or NT-proBNP and hsTnT, both IGFBP7 and GDF-15 independently predicted all-cause mortality, hazard ratios 2.13[1.08–4.22] and 2.03[1.62–2.56] per unit increase of Ln-transformed markers, respectively.

Conclusions: In a community-based elderly cohort, IGFBP7 and GDF-15 appear associated to cardiac alterations as well as to 10-year risk of all-cause mortality.

Keywords: IGFBP7, GDF-15, P1NP, Cardiac remodelling, Community-dwelling elderly

Background

Cardiovascular remodelling in the elderly is a complex phenomenon, which involves different pathways including hypertrophy, fibrosis, and cell death. Players are not limited to cardiac myocytes, but include fibroblasts, endothelial and smooth-muscle vascular cells. Several biomarkers have been made available over the recent
years as possible readouts of the different processes involved [1].

In particular, insulin-like growth factor-binding protein-7 (IGFBP7) has been identified as a cellular senescence marker [2]. IGFBP7 is associated with cardiac structural and functional abnormalities, including hypertrophy, diastolic dysfunction and poor prognosis in patients with heart failure (HF) with and without atrial fibrillation (AF) [3–5]. These observations have been recently extended to insulin resistance and metabolic syndrome [6, 7]. Little is known on the clinical value of IGFBP7 in elderly general population with multiple comorbidities and high prevalence of asymptomatic cardiovascular ventricular dysfunction.

Since inflammation and fibrosis are hallmarks of cardiac aging and remodelling, we compared the clinical performance of IGFBP7 with 2 other biomarkers reflecting these pathogenic pathways, i.e. the growth differentiation factor-15 (GDF-15) [8] and amino-terminal pro-peptide of type I procollagen (P1NP) [9]. GDF-15 is a member of the transforming growth factor-beta superfamily. Several studies have shown the strong prognostic value of GDF-15 in the general population [10, 11] and its relation with cardiac remodelling [12]. P1NP is a circulating marker of bone turnover, used to monitor evolution of osteoporosis [13]; P1NP was found altered in patients with HF indicating the activation of pro-fibrotic signalling and their prognostic relevance [14].

The PREDICTOR cohort of 2001 community-dwelling subjects aged 65–84 years was chosen since all subjects had undergone echocardiography, centrally read, and long-term outcome data were made available through administrative registries [15]. Taking the opportunity of the good characterization of the population and of the long-term follow-up, the present study was conducted with two complementary aims:

- To assess the relation of IGFBP7, GDF-15 and P1NP with atrial fibrillation, left ventricular hypertrophy (LVH), reduced mid-wall circumference fraction shortening (MFS), E/e', and enlarged left atrium in an elderly community dwelling cohort;
- To estimate the long-term prognostic value for fatal and non-fatal clinical events.

Methods

Study population

PREDICTOR (Valutazione della PREvalenza di DIfunzione Cardiaca asinTOmatica e di scompenso caRdiaico) was a cross-sectional, population-based study of the prevalence of asymptomatic LV dysfunction and heart failure (HF) in 2001 elderly people aged 65–84 years resident in the Lazio region of Italy.

The design of the PREDICTOR study has been described in detail [15]. A random sample of 5940 residents, 65–84 years old, from four cities (Rome, Civitavecchia, Frosinone, and Viterbo) in the Lazio region was identified based on the Regional Health Registry. Between June 2007 and January 2010, a total of 2001 subjects provided written informed consent. Participants were referred to eight cardiology centres in the Lazio region for clinical examination, blood tests, electrocardiography, comprehensive Doppler echocardiography and blood sampling to measure circulating biomarkers.

The Hospital Information System (HIS) provided data on hospitalizations occurred after the PREDICTOR baseline visit, while the Regional Mortality Registry provided mortality status with cause of death. Data from these two sources were linked through standardized methods based on a unique, anonymous, personal identifier, as reported elsewhere [16, 17]. A complete list of participating centres and investigators has been published [15]. Approval for this study was obtained from the local ethics committee.

Participants were followed-up from mid-2007 until 31st of December 2019 for all-cause mortality and hospitalization. Cause-specific mortality and hospitalization data was also available until 31 December, 2017. The ICD9 (mortality data) and ICD9CM (hospitalization data) codes 390–459 were classified as ‘cardiovascular’ and ICD9 code 428.x was classified as heart failure [18].

Circulating biomarkers

Venous blood samples from fasted subjects were collected with participants resting in the supine position for at least 15 min. Blood samples were collected in tubes containing ethylenediamine tetraacetic acid tripotassium salt (EDTA). Blood was centrifuged at 2000 g at 4 °C within 10 min and aliquots of plasma were immediately frozen and subsequently transported on dry ice to a central laboratory. Samples were stored at –70 °C until they were assayed. Plasma concentrations of all biomarkers were assayed in a central laboratory by personnel blinded to the identity of each sample. NT-proBNP, hs-cTnT, GDF-15, P1NP, were measured by electrochemiluminescence immunoassay using commercial reagents (cobas Elecsys® 2010, Roche Diagnostics GmbH, Mannheim). The cardiac biomarkers, hs-cTnT and NT-proBNP, were used as benchmark.

IGFBP7 was measured using a preclinical research-use only assay on an automated platform (Roche Diagnostics GmbH, Penzberg, Germany). The detection method for IGFBP7 was a sandwich immunoassay developed on the Elecsys® platform for electrochemiluminescence
convenience in Additional file 1: Supplemental Material. GDF-15, P1NP, hs-cTnT and NT-proBNP) were assessed as median [Q1–Q3] and compared by Kruskal–Wallis. 

Of ANOVA while non-parametric variables are expressed as proportions. Normally distributed continuous variables are presented as mean (SD) and compared by means of ANOVA while non-parametric variables are expressed as median [Q1–Q3] and compared by Kruskal–Wallis. 


determination of altered echocardiographic patterns (Table 2). Age, creatinine, diabetes and atrial fibrillation were strongly, independently associated with GDF-15 in multivariate regression model (all p < 0.0001).

Tertiles 2 and 3 of GDF-15 were older, had significantly higher creatinine levels as well as a larger proportion males and smokers. Higher GDF-15 was associated with more patients with diabetes, angina pectoris, myocardial infarction, atrial fibrillation and COPD. Tertile 3 of GDF-15 was associated with higher concentrations of all circulating biomarkers except for P1NP. In addition, higher GDF-15 were associated with higher proportions of altered echocardiographic patterns (Table 2). Age, creatinine, diabetes and atrial fibrillation were strongly, independently associated with GDF-15 in multivariate regression model (all p < 0.0001).

P1NP was higher in females, in non-diabetics and in non-smokers (Table 3). Upon including these variables
| Table 1 | Demographic, clinical and echocardiographic characteristics according to tertiles of IGF BP 7 |
|---------|--------------------------------------------------------------------------------------------------|
|         | Total N = 1913 | IGFBP7 (ng/mL) N = 631 | Terterle 2 N = 632 | Terterle 3 N = 650 | p       |
| IGFBP7  | Median [IQR]   | 165.5 [150.7–183.6]   | 145.4 [138.0–150.6] | 165.1 [160.2–170.5] | 193.9 [182.8–210.3] | –       |
| Range   | 92.4–617.8     | 92.4–155.2             | 155.3–175.8         | 175.9–617.8          | –       |
| Age, years | Mean ± SD     | 72.7 ± 5.0             | 70.8 ± 4.1           | 72.2 ± 4.5           | 75.2 ± 5.2 | 3.4 × 10⁻¹⁰¹ |
| Females | N (%)          | 925 (48.4)             | 366 (58.0)           | 309 (48.9)           | 250 (38.5) | 2.2 × 10⁻¹ⁱ |
| BMI, kg/m² | Mean ± SD   | 26.5 ± 4.2             | 26.2 ± 4.0           | 26.7 ± 4.1           | 26.5 ± 4.3 | 0.084 |
| BSA, m² | Mean ± SD     | 1.80 ± 0.19            | 1.77 ± 0.18          | 1.82 ± 0.20          | 1.83 ± 0.18 | 6.4 × 10⁻⁹ |
| Serum creatinine, mg/dL | Mean ± SD | 0.96 ± 0.26            | 0.85 ± 0.17          | 0.93 ± 0.19          | 1.10 ± 0.33 | 1.6 × 10⁻⁷ |
| eGFR, mL/min/1.73 m² | Mean ± SD | 69.6 ± 21.1            | 75.6 ± 19.8          | 72.2 ± 21.5          | 61.0 ± 19.0 | 1.4 × 10⁻¹⁸ |
| CKD (eGFR < 60) | N (%) | 632 (33.4%)            | 123 (19.6%)          | 176 (27.9%)          | 333 (52.2%) | 3.6 × 10⁻³⁶ |
| Clinical history | | | | | | |
| Hypertension | N (%) | 1132 (59.2)            | 357 (56.6)           | 375 (59.3)           | 400 (61.5) | 0.195 |
| Diabetes mellitus | N (%) | 313 (16.5)             | 91 (14.6)            | 91 (14.4)            | 131 (20.2) | 0.006 |
| Smoking | N (%)          | 252 (13.2)             | 88 (13.9)            | 83 (13.2)            | 81 (12.5) | 4.1 × 10⁻⁷ |
| Alcohol use | N (%)        | 1128 (59.0)            | 367 (58.2)           | 382 (60.5)           | 379 (58.3) | 0.628 |
| Dyslipidemia | N (%)        | 828 (44.3)             | 302 (49.2)           | 268 (43.1)           | 258 (40.8) | 0.009 |
| Angina pectoris | N (%) | 121 (6.3)              | 41 (6.5)             | 41 (6.5)             | 39 (6.0) | 0.916 |
| Myocardial infarction | N (%) | 116 (6.1)              | 34 (5.4)             | 28 (4.5)             | 54 (8.4) | 0.010 |
| Atrial fibrillation | N (%) | 132 (6.9)              | 28 (4.4)             | 35 (5.5)             | 69 (10.6) | 1.9 × 10⁻⁵ |
| Heart failure | N (%)        | 114 (6.3)              | 18 (3.0)             | 35 (5.7)             | 61 (10.0) | 2.0 × 10⁻⁶ |
| AHA/ACC class | | | | | | |
| Normal | N (%)          | 242 (12.7)             | 104 (16.5)           | 85 (13.4)            | 53 (8.2) | 1.8 × 10⁻⁷ |
| A | N (%)          | 444 (23.2)             | 148 (23.5)           | 139 (22.0)           | 157 (24.2) | |
| B | N (%)          | 1113 (58.2)            | 361 (57.2)           | 373 (59.0)           | 379 (58.3) | |
| C | N (%)          | 114 (6.0)              | 18 (2.9)             | 35 (5.5)             | 61 (9.4) | |
| COPD | N (%)          | 171 (8.9)              | 48 (7.6)             | 56 (8.9)             | 67 (10.3) | 0.237 |
| Circulating biomarkers | | | | | | |
| GDF-15, pg/mL | Median [IQR] | 1468 [1168–1984]      | 1250 [1021–1527]     | 1405 [1168–1761]     | 1915 [1445–2603] | 3.7 × 10⁻⁸ |
| P1NP, ng/mL | Median [IQR] | 35.2 [26.3–46.0]      | 32.6 [24.5–42.6]     | 34.9 [26.0–45.5]     | 37.2 [27.5–51.3] | 2.9 × 10⁻⁷ |
| hs cTnT, ng/L | Median [IQR] | 5.5 [3.0–9.5]         | 3.5 [3.0–6.3]        | 5.0 [3.0–8.2]        | 8.1 [4.9–13.7] | 5.7 × 10⁻⁵ |
| NT-proBNP, ng/L | Median [IQR] | 92 [47–186]          | 63 [36–123]          | 81 [45–151]          | 142 [69–293] | 8.9 × 10⁻⁴ |
| Echocardiography | | | | | | |
| LVEF, % (N = 1858) | Mean ± SD | 66.3 ± 7.2             | 66.9 ± 6.2           | 66.7 ± 6.9           | 65.2 ± 8.3 | 8.1 × 10⁻⁵ |
| LAA -, cm² (N = 1332) | Mean ± SD | 11.1 ± 4.1             | 10.4 ± 3.6           | 10.9 ± 3.5           | 11.9 ± 4.9 | 8.1 × 10⁻⁷ |
| LV mass / BSA, g/m² (N = 1489) | Mean ± SD | 91.9 ± 23.3            | 87.4 ± 19.5          | 92.7 ± 23.8          | 95.8 ± 25.4 | 2.5 × 10⁻⁸ |
| LVH (N = 1853) | N (%)          | 373 (24.4)             | 99 (18.9)            | 127 (25.1)           | 147 (29.3) | 4.9 × 10⁻⁴ |
| MFS reduced (N = 1470) | N (%) | 448 (31.9)              | 136 (28.6)           | 137 (29.6)           | 175 (37.5) | 0.006 |
| E/e' > 8 (N = 1801) | N (%) | 765 (44.4)              | 216 (38.0)           | 261 (45.5)           | 288 (49.7) | 3.2 × 10⁻⁴ |
| Enlarged LA-area (N = 1332) | N (%) | 41 (3.2)                | 7 (1.7)              | 8 (1.8)              | 26 (6.2) | 1.2 × 10⁻⁴ |
| Outcomes (N = 1715) | | | | | | |
| All-cause mortality | N (%) | 491 (30.0)             | 104 (19.7)           | 130 (23.8)           | 257 (45.7) | 4.9 × 10⁻²³ |
| CV mortality | N (%)          | 115 (6.0)              | 19 (3.0)             | 24 (3.8)             | 72 (11.1) | 1.6 × 10⁻¹⁰ |
| Hospitalization | N (%) | 1297 (79.3)            | 392 (74.4)           | 439 (80.3)           | 466 (82.9) | 0.002 |
| CV hospitalization | N (%) | 583 (35.6)             | 143 (27.1)           | 210 (38.4)           | 230 (40.9) | 3.0 × 10⁻⁶ |
| HF hospitalization | N (%) | 168 (10.3)              | 25 (4.7)             | 50 (9.1)             | 93 (16.3) | 6.7 × 10⁻¹⁰ |
in multivariable regression, only diabetes, sex creatinine and age were associated with higher P1NP.

Relationship between concentrations of the 3 biomarkers and echocardiographic variables
Atrial fibrillation and four echocardiographic patterns were dichotomized by presence vs absence: increased E/e’, enlarged LAA, left ventricular hypertrophy, and reduced mid-wall circumference fraction shortening. Ln-transformed IGFBP7 was associated with all variables after adjustment for age and sex. All echocardiographic characteristics, except for enlarged LAA, were independently associated to Ln-transformed GDF-15, whereas Ln-transformed P1NP was not associated with any echocardiographic characteristic (Table 4).

Prognostic value of IGFBP7 and GDF-15
During a median of 10.6 years of follow-up, 526 patients (26.3%) died, and 1365 (68.2%) were admitted to hospital for any reason. Both IGFBP7 and GDF-15 had significantly higher all-cause and cardiovascular mortality in their highest tertiles as well as a significantly increased all-cause and cardiovascular hospitalization. On the contrary, P1NP appeared totally unrelated to study outcomes (data not shown).

Figure 1 shows the Kaplan–Meier survival curves for these outcomes (all-cause and cardiovascular mortality and hospitalization). In general, patients in tertile 3 had worse outcomes, as evident from Tables 1 and 2. In univariate Cox analyses, increased concentrations of IGFBP7 and GDF-15 predicted mortality and hospitalization either all-cause or cardiovascular (Table 5). After adjustment for clinical variables, the association with all-cause and cardiovascular mortality remained significant for both IGFBP7 and GDF-15: HR 2.13[1.08–4.22] and 2.03[1.62–2.56] per unit increase of Ln-transformed markers, respectively. Upon adjusting for echocardiographic variables (e.g. MFS and enlarged LAA) or biomarkers (e.g. NT-proBNP and hsTnT), IGFBP7 and GDF-15 no longer independently predicted hospitalizations but only mortality.

In addition, IGFBP7 and more so GDF-15 predicted cancer mortality (147 events, 27.9% of all deaths). Death rates for cancer in the upper tertile of GDF-15 and IGFBP7 were 11.5% and 9.7%, compared to 3.9% and 6.0% in the lower tertile (p < 0.0001 and p = 0.011, respectively). In addition, Cox proportional hazard regression analyses, adjusted for age, sex, systolic blood pressure, diabetes, COPD, alcohol consumption, atrial fibrillation, heart failure, smoking, dyslipidemia, history of ischemic heart disease, LVEF and LV mass/BSA, showed significant results for both IGFBP7 (HR:3.97 [95% CI 1.16–13.58], p = 0.028) and GDF15 (HR: 2.04 [1.30–3.19], p = 0.002).

Discussion
In a cross-sectional epidemiological study including almost 2000 community-dwelling elderly persons (65–84 years) living in the region of Rome, Italy, and followed up for 10 years, the novel biomarker IGFBP7 was found to be associated with cardiac characteristics related to aging, such as LV hypertrophy and mild LV systolic dysfunction. Atrial fibrillation, enlarged LAA and E/e’ > 8 were also associated with higher concentrations of IGFBP7. IGFBP7 was also independently associated with mortality, all-cause as well as cardiovascular.

Similarly, GDF-15 was found to be associated with echocardiographic variables such as LVH and MFS, atrial fibrillation and E/e’ > 8. In addition, after adjusting for clinical characteristics, GDF-15 was predictive for mortality (both all-cause and cardiovascular). On the other side, P1NP, a marker of fibrosis, did not show any association with cardiac phenotypes or with outcomes (data not shown). If other circulating markers of collagen turnover, such as PIINP, PICP had been assayed, more encouraging results may have been obtained [21]. In general, the concentrations of IGFBP7 and GDF-15 were lower than those reported in other studies, focused on patients with cardiovascular disease. Indeed, in the present elderly cohort, the prevalence of heart failure and of history of myocardial infarction was very low, respectively 6.3% and 6.1%.

IGFBP7 and the other 2 biomarkers, GDF-15 and P1NP, were chosen since they covered different aspects of cardiac diseases, such as inflammation, apoptosis, fibrosis, and were described as specifically linked to one or more cardiac phenotypes. IGFBP7, a novel prognostic biomarker for heart failure, has been suggested also as a marker for diastolic dysfunction in patients with heart failure with preserved EF, at risk of disease progression [6, 22, 23]. In PREDICTOR, IGFBP7 showed the best association with all cardiac phenotypes. This finding in community-dwelling elder individuals is in agreement with previous studies in patients [13–15].
Table 2  Demographic, clinical and echocardiographic characteristics according to tertiles of GDF-15

|                                | Total               | GDF-15 (pg/mL)                    |      |      |      |
|--------------------------------|---------------------|-----------------------------------|------|------|------|
|                                | N = 1907            | N = 642                           | N = 625 | N = 640 |      |
| GDF-15 Median [IQR]            | 1468 [1168–1984]    | 1059 [932–1168]                  | 1460 [1368–1605] | 2267 [1960–2991] | –     |
| Range                          | 592–13,015          | 592–1272                         | 1273–1760   | 1762–13,015 |      |
| Age, years                     | Mean±SD             | 72.9±5.0                         | 70.6±3.8   | 72.9±4.7   | 75.1±3.5   | 5.6 x 10⁻⁶⁶ |
| Females N (%)                  | 962 (48.3%)         | 393 (59.6%)                      | 316 (48.2%) | 253 (37.4%) | 4.9 x 10⁻¹⁵ |
| BMI, kg/m² Mean±SD             | 26.5±4.2            | 26.2±4.2                         | 26.7±4.1   | 26.5±4.2   | 0.105   |
| BSA, m² Mean±SD                | 1.80±0.19           | 1.78±0.19                        | 1.81±0.19   | 1.82±0.18   | 1.8 x 10⁻⁴    |
| Serum creatinine, mg/dL⁻¹      | Mean±SD             | 0.96±0.27                        | 0.87±0.20   | 0.94±0.21   | 1.07±0.33  | 2.9 x 10⁻⁶⁶ |
| eGFR, mL/min/1.73m² Mean±SD    | 69±3±210.0          | 75.2±21.3                        | 70.0±19.4   | 62.9±20.6   | 2.9 x 10⁻⁶⁶ |
| CKD (eGFR < 60) N (%)          | 671 (34.0%)         | 141 (12.5%)                      | 209 (32.3%) | 321 (48.1%) | 1.0 x 10⁻²³ |
| Clinical history               |                     |                                  |            |            |      |
| Hypertension N (%)             | 1183 (59.4%)        | 385 (58.4%)                      | 394 (60.2%) | 404 (59.8%) | 0.798   |
| Diabetes mellitus N (%)        | 330 (16.7%)         | 47 (7.2%)                        | 94 (14.5%)  | 189 (28.0%) | 6.2 x 10⁻²⁴ |
| Smoking N (%)                  | 259 (13.0%)         | 49 (7.4%)                        | 86 (13.1%)  | 124 (18.4%) | 7.5 x 10⁻¹⁵ |
| Alcohol use N (%)              | 1170 (58.8%)        | 399 (60.5%)                      | 386 (58.9%) | 385 (57.0%) | 0.427   |
| Dyslipidaemia N (%)            | 854 (43.9%)         | 289 (44.6%)                      | 300 (46.9%) | 265 (40.2%) | 0.046   |
| Angina pectoris N (%)          | 123 (6.2%)          | 24 (3.6%)                        | 35 (5.3%)   | 64 (9.5%)   | 3.2 x 10⁻⁵    |
| Myocardial infarction N (%)    | 122 (6.2%)          | 16 (2.4%)                        | 34 (5.2%)   | 72 (10.7%)  | 1.4 x 10⁻⁹    |
| Atrial fibrillation N (%)      | 153 (7.7%)          | 29 (4.4%)                        | 44 (6.7%)   | 80 (11.8%)  | 1.0 x 10⁻⁶    |
| Heart failure N (%)            | 127 (6.7%)          | 15 (2.4%)                        | 35 (5.6%)   | 77 (12.3%)  | 6.0 x 10⁻¹²   |
| AHA/ACC class                  |                     |                                  |            |            |      |
| Normal N (%)                   | 249 (12.5%)         | 112 (17.0%)                      | 82 (12.5%)  | 55 (8.1%)   | 2.2 x 10⁻¹²   |
| A                                | 466 (23.4%)         | 158 (24.0%)                      | 153 (23.4%) | 155 (22.9%) |      |
| B                                | 1148 (57.7%)        | 374 (56.8%)                      | 385 (58.8%) | 389 (57.5%) |      |
| C                                | 127 (6.4%)          | 15 (2.3%)                        | 35 (5.3%)   | 77 (11.4%)  |      |
| COPD N (%)                      | 178 (8.9%)          | 34 (5.2%)                        | 67 (10.2%)  | 77 (11.4%)  | 1.3 x 10⁻⁴    |
| Circulating biomarkers          |                     |                                  |            |            |      |
| IGFBP7, ng/mL Median [IQR]     | 166 [151–184]       | 155 [144–167]                    | 166 [153–179] | 182 [163–203] | 4.0 x 10⁻³⁰ |
| P1NP, ng/mL Median [IQR]       | 35.2 [26.3–46.0]    | 35.1 [26.8–44.8]                 | 35.4 [26.6–45.1] | 35.1 [25.7–49.3] | 0.756   |
| hs cTnT, ng/L Median [IQR]     | 5.5 [3.0–9.5]       | 3.3 [3.0–5.9]                    | 5.6 [3.0–9.0] | 8.5 [4.9–14.1] | 2.8 x 10⁻⁶⁹ |
| NT-proBNP, ng/L Median [IQR]   | 92 [47–186]         | 66 [37–122]                      | 90 [47–180]  | 135 [66–299] | 1.1 x 10⁻³²   |
| Echocardiography               |                     |                                  |            |            |      |
| LVEF, % (N = 1858)             | Mean±SD             | 66.1±7.4                         | 67.0±6.2   | 66.5±6.8   | 64.6±8.8   | 4.4 x 10⁻⁴     |
| LAA−, cm² (N = 1332)           | Mean±SD             | 11.2±4.4                         | 10.7±3.8   | 11.1±4.3   | 12.0±4.9   | 1.9 x 10⁻⁵     |
| LV mass / BSA, g/m² (N = 1489) | Mean±SD             | 92.2±23.2                        | 87.9±20.3  | 91.1±22.0  | 98.1±26.3  | 2.4 x 10⁻¹²    |
| LVH (N = 1853)                 | N (%)               | 396 (24.8%)                      | 119 (21.0%) | 119 (22.6%) | 158 (31.5%) | 1.2 x 10⁻⁴     |
| MFS reduced (N = 1470)         | N (%)               | 471 (32.2%)                      | 120 (23.4%) | 159 (32.6%) | 195 (41.4%) | 1.6 x 10⁻⁸     |
| E/e' > 8 (N = 1801)            | N (%)               | 801 (44.7%)                      | 239 (39.6%) | 262 (43.9%) | 300 (50.8%) | 0.001     |
| Enlarged LA-area (N = 1332)    | N (%)               | 54 (4.1%)                        | 10 (2.1%)  | 18 (4.1%)  | 26 (6.2%)  | 0.008     |
| Outcomes (N = 1715)            |                     |                                  |            |            |      |
| All-cause mortality N (%)      | 526 (30.8%)         | 81 (14.8%)                       | 139 (24.6%) | 306 (51.4%) | 5.6 x 10⁻⁴³ |
| CV mortality N (%)             | 125 (6.3%)          | 14 (2.1%)                        | 33 (5.0%)   | 78 (11.5%)  | 3.4 x 10⁻¹² |
| Hospitalization N (%)          | 1360 (79.7%)        | 410 (75.0%)                      | 448 (79.3%) | 502 (84.4%) | 4.0 x 10⁻⁴ |
| CV hospitalization N (%)       | 613 (35.9%)         | 153 (28.0%)                      | 192 (34.0%) | 268 (45.0%) | 7.4 x 10⁻⁹ |
Some features are worth mentioning. IGFBP7 and GDF-15 markedly increased with age, while this trend for P1NP was weaker, with a borderline statistical significance ($p = 0.035$). Females were significantly less frequent in the highest tertile of IGFBP7 and GDF-15, while the opposite was true for P1NP. This last finding is attributable to the loss of estrogen production due to menopause [24].

Serum creatinine, and consequently eGFR, significantly increased over tertiles of IGFBP7 and of GDF-15, but not of P1NP, which was unrelated to serum creatinine. The presence of diabetes mellitus was strongly associated with higher levels of GDF-15 and to a lesser extent of IGFBP7. In a cohort of 4360 Swedish non-diabetic individuals, GDF-15 was shown to be a strong independent predictor of risk of incident diabetes [25]. While the authors reported that the predictive power of GDF-15 was lost beyond 60 years of age, in PREDICTOR, a cohort with a mean age of 73, higher concentrations of GDF-15 were strongly associated with the presence diabetes mellitus.

The trend for P1NP goes in the opposite direction: the prevalence of diabetes mellitus is significantly higher in the lower tertile of P1NP. Indeed, it has been consistently shown that insulin resistance [26] and overt diabetes mellitus decrease circulating concentrations of markers of bone turnover such as P1NP [27, 28].

Unexpectedly, smokers were significantly more frequent in the lower tertile of concentrations of IGFBP7; however, the statistical significance disappeared in the multivariable analysis: younger age of smokers may well explain this univariate association. On the other side, the markedly higher prevalence of smokers in the highest tertile of GDF-15 has been reported in a Framingham cohort of subjects without overt cardiovascular disease [29]. Abundant evidence exists on association of GDF-15 with impaired endothelial function, arterial stiffness [30], carotid plaques [31], and higher coronary calcium scores [32]. The higher prevalence of history of MI, angina pectoris and atrial fibrillation in particular, goes along the same line of evidence on GDF-15, a cytokine produced in cardiovascular cells under the effect of inflammation and oxidative stress.

In a cohort of 228 patients with HFpEF, IGFBP7 and GDF-15 were found to be related to LV structure, function, and to the burden of comorbidities [33]. The results of PREDICTOR confirm the association of both biomarkers with LV structure and function, in particular with an impaired LV filling. In addition, IGFBP7 and GDF-15 showed for the first time to predict 10-year risk of CV and non-CV major events.

Altogether, the evidence on the three circulating biomarkers assayed in the PREDICTOR community dwelling elderly individuals confirms and extends the findings of previous studies, while it supports a comprehensive assessment of the novel molecule IGFBP7 in relation to cardiac function and clinical outcomes.

The following features of PREDICTOR study strengthen the results presented: identification of subjects through the registry of the National Health Service [15], long-term assessment of outcomes through the same administrative registry, central reading of all echocardiographic exams in a single core laboratory under blind conditions, assay of all anonymized plasma samples for the circulating biomarkers in a central laboratory (Roche Diagnostics GmbH, Penzberg, Germany). A limitation of this study is that the predictive analyses have only been performed for the 1715 patients who could be matched to the Hospital Information System. The remaining 14.3% of the cases were not matched, which may introduce some selection bias. Upon comparing the clinical characteristics of the patients with and without FU available, we found that those with FU available had more often a history of atrial fibrillation and a high AHA/ACC class. In addition, we estimated the statistical power to detect any modest effects on clinical endpoints. For IGFBP7, at an alpha of 0.05, we had at least 80% power for all-cause mortality in the full sample if the true HR was 1.40. For GDF-15, we had at least 80% power for all-cause mortality in the full sample if the true HR was 1.35 with an alpha of 0.05. For IGFBP7 and GDF-15, we had at least 80% power for all-cause mortality in the full sample if the true HR was 1.40. For GDF-15, we had at least 80% power for all-cause mortality in the full sample if the true HR was 1.35 with an alpha of 0.05. For all cause hospitalization, for both IGFBP7 and GDF15, with an alpha of 0.05 we had at least 80% power if the true HR was 1.20.

The specificity of a biomarker for a defined cardiac phenotype remains to be elucidated. In fact, there is no such thing as pure/isolated fibrosis without some cardiac myocyte injury and inflammatory activation; on the other hand, myocardial hypertrophy coexists with some interstitial fibrosis. Accordingly, IGFBP7 and GDF-15, two molecules found to be related with cancer and not only with cardiovascular disease states, in the PREDICTOR

### Table 2 (continued)

| Biomarker | Males | Females | p value |
|-----------|-------|---------|---------|
| IGFBP7 | 85% | 75% | 0.035 |
| GDF-15 | 65% | 55% | 0.02 |
| P1NP | 55% | 45% | 0.001 |

BMI, body mass index; BSA, body surface area; CKD, chronic kidney disease defined as eGFR < 60; CV, cardiovascular; COPD, chronic obstructive pulmonary disease; E/e’ > 8 vs < 8; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; hs cTnT, high sensitivity cardiac troponin T; IGFBP7, insulin growth factor binding protein; LAA, left atrial area, enlarged if > 20 cm²; LVEF, left ventricular ejection fraction; LVH: Left ventricular hypertrophy defined as LV mass/BSA > 95 g/m² for women and > 115 g/m² for men; MFS, midwall circumference fraction shortening, reduced if MFS < 15%; NTproBNP, N-terminal probrain natriuretic peptide; P1NP, amino-terminal propeptide of type I procollagen. Continuous data is presented either as mean ± SD or median [IQR].
| Clinical history | Total | P1NP Tertile 1 | P1NP Tertile 2 | P1NP Tertile 3 | p |
|------------------|-------|----------------|----------------|----------------|---|
| Age, years       | Mean ± SD | 67.5 ± 10.0 | 66.2 ± 10.2 | 68.4 ± 10.7 | 0.004 |
| Females          | N (%) | 1171 (58.8%) | 405 (61.8%) | 401 (60.8%) | 365 (54.0%) | 0.006 |
| BMI, kg/m²       | Mean ± SD | 26.5 ± 4.2 | 26.5 ± 4.2 | 26.7 ± 4.3 | 26.3 ± 4.2 | 0.192 |
| BSA, m²          | Mean ± SD | 1.80 ± 0.19 | 1.82 ± 0.18 | 1.81 ± 0.20 | 1.77 ± 0.18 | 0.063 |
| Serum creatinine, mg/dL⁻¹ | Mean ± SD | 1.09 ± 0.27 | 1.06 ± 0.26 | 1.09 ± 0.32 | 0.947 |
| eGFR, mL/min/1.73m² | Mean ± SD | 69.3 ± 21.0 | 70.7 ± 20.4 | 70.6 ± 22.3 | 66.7 ± 20.2 | 3.8 × 10⁻⁴ |
| CKD (eGFR < 60)  | N (%) | 671 (34.0%) | 206 (31.5%) | 212 (32.6%) | 253 (37.9%) | 0.030 |
| Hypertension     | N (%) | 1183 (59.4%) | 387 (59.0%) | 388 (58.9%) | 408 (60.4%) | 0.829 |
| Diabetes mellitus| N (%) | 330 (16.7%) | 148 (22.7%) | 98 (15.0%) | 84 (12.5%) | 0.20 × 10⁻⁵ |
| Smoking          | N (%) | 259 (13.0%) | 89 (13.6%) | 93 (14.1%) | 77 (11.4%) | 1.2 × 10⁻⁴ |
| Alcohol use      | N (%) | 1171 (58.8%) | 405 (61.8%) | 401 (60.8%) | 365 (54.0%) | 0.006 |
| Dyslipidaemia    | N (%) | 854 (43.9%) | 290 (45.3%) | 284 (44.3%) | 280 (42.0%) | 0.474 |
| Angina pectoris  | N (%) | 123 (6.2%) | 47 (7.2%) | 38 (5.8%) | 38 (5.6%) | 0.437 |
| Myocardial infarction | N (%) | 122 (6.2%) | 42 (6.4%) | 37 (5.7%) | 43 (6.4%) | 0.792 |
| Atrial fibrillation | N (%) | 153 (7.7%) | 45 (6.9%) | 55 (8.3%) | 53 (7.8%) | 0.589 |
| COPD             | N (%) | 178 (8.9%) | 67 (10.2%) | 56 (8.5%) | 55 (8.1%) | 0.368 |
| Heart failure    | N (%) | 127 (6.7%) | 38 (6.1%) | 41 (6.6%) | 48 (7.5%) | 0.605 |
| AHA/ACC class    | N (%) | 1148 (57.7%) | 388 (59.1%) | 355 (53.9%) | 405 (59.9%) | 0.400 |
| Normal           | N (%) | 250 (12.6%) | 78 (11.9%) | 85 (12.9%) | 87 (12.9%) | 0.103 |
| A                | N (%) | 466 (23.4%) | 152 (23.2%) | 178 (27.0%) | 136 (20.1%) | 0.192 |
| B                | N (%) | 1148 (57.7%) | 388 (59.1%) | 355 (53.9%) | 405 (59.9%) | 0.400 |
| C                | N (%) | 127 (6.4%) | 38 (5.8%) | 41 (6.2%) | 48 (7.1%) | 0.437 |
| Circulating biomarkers | N (%) | 1148 (57.7%) | 388 (59.1%) | 355 (53.9%) | 405 (59.9%) | 0.400 |
| IGFBP7, ng/mL    | Median [IQR] | 166 [151–184] | 163 [149–179] | 164 [149–182] | 170 [154–192] | 2.2 × 10⁻⁷ |
| GDF-15, pg/mL    | Median [IQR] | 1468 [1168–1984] | 1478 [1160–2046] | 1435 [1160–1878] | 1499 [1186–2070] | 0.058 |
| hs cTnT, ng/L    | Median [IQR] | 5.5 [3.0–9.5] | 6.0 [3.0–9.8] | 5.2 [3.0–8.6] | 5.4 [3.0–10.4] | 0.147 |
| NT-proBNP, ng/L | Median [IQR] | 92 [47–186] | 85 [43–167] | 87 [45–169] | 112 [53–219] | 9.0 × 10⁻⁶ |
| Echocardiography and outcomes | N (%) | 1148 (57.7%) | 388 (59.1%) | 355 (53.9%) | 405 (59.9%) | 0.400 |
| LV EF, %         | Mean ± SD | 66.1 ± 7.4 | 66.0 ± 7.6 | 66.2 ± 7.1 | 65.9 ± 7.5 | 0.803 |
| LAA, cm²         | Mean ± SD | 112 ± 44 | 11.2 ± 4.4 | 11.0 ± 4.3 | 11.6 ± 4.6 | 0.105 |
| LV mass / BSA, g/m² | Mean ± SD | 92.2 ± 23.2 | 94.2 ± 24.5 | 91.5 ± 23.2 | 90.9 ± 21.8 | 0.045 |
| LVH              | N (%) | 396 (24.8%) | 128 (23.9%) | 123 (23.6%) | 145 (26.9%) | 0.400 |
| MFS reduced      | N (%) | 471 (32.2%) | 170 (34.2%) | 144 (30.4%) | 157 (31.8%) | 0.435 |
| E/e’ > 8         | N (%) | 801 (44.7%) | 267 (45.4%) | 239 (40.2%) | 295 (48.4%) | 0.016 |
| Enlarged LA-area | N (%) | 54 (4.1%) | 16 (3.7%) | 15 (3.4%) | 23 (5.1%) | 0.413 |
| All-cause mortality | N (%) | 526 (30.8%) | 169 (30.0%) | 159 (28.3%) | 198 (34.0%) | 0.008 |
| CV mortality     | N (%) | 125 (6.3%) | 38 (5.8%) | 35 (5.3%) | 52 (7.7%) | 0.165 |
| Hospitalization  | N (%) | 1360 (79.7%) | 455 (80.8%) | 443 (78.8%) | 462 (79.4%) | 0.693 |
| CV hospitalization | N (%) | 613 (35.9%) | 217 (38.5%) | 188 (33.5%) | 208 (35.7%) | 0.204 |
| HF hospitalization | N (%) | 184 (10.8%) | 60 (10.7%) | 50 (8.9%) | 74 (12.7%) | 0.114 |
Cohort were found to predict not only all-cause mortality, but also the probability of cancer death after full adjustments (Table 5). This evidence is consistent with other community-dwelling elderly studies [34, 35].

Conclusions
In conclusion, the peculiar feature of the present study is the comparative evaluation of three circulating biomarkers in about 2000 community-dwelling elderly with a follow-up of over 10 years. The significant association of GDF-15 with structural and functional cardiac alterations confirms previous results from the Framingham population [36]. However, similar findings for IGFBP7 in a community-based elderly cohort is novel. In addition, the 10-year follow-up allowed to show the independent predictive power of both IGFBP7 and GDF-15, which was markedly reduced if not cancelled by the presence of NT-proBNP and hs-cTnT in the multivariable models. Both IGFBP7 and GDF15 independently predict mortality and hospitalization for heart failure. This suggests that either these two molecules are directly related to outcomes (quite unlikely) or that their effects on outcomes is mediated, at least in part, by unidentified processes. This is consistent with what already found for NT-proBNP and hs-cTnT [15, 37], both reliable readouts of cardiac injury and dysfunction, but not playing causal roles.

Table 3 (continued)
BMI, body mass index; BSA, body surface area; CKD, chronic kidney disease defined as eGFR < 60; CV, cardiovascular; COPD, chronic obstructive pulmonary disease; E/e' > 8 vs ≤ = 8; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; hs cTnT, high sensitivity cardiac troponin T; IGFBP7, insulin growth factor binding protein; LAA, left atrial area, enlarged if > 20 cm²; LVH, left ventricular hypertrophy defined as LV mass/BSA > 95 g/m² for women and > 115 g/m² for men; MFS, midwall circumference fraction shortening, reduced if MFS < 15%; NT-proBNP, N-terminal probrain natriuretic peptide; P1NP, amino-terminal propeptide of type I procollagen. Continuous data is presented either as mean ± SD or median [IQR]

Table 4 Results of logistic regression models
| Dependent variable | Univariate | | Adjusted by age and sex | | Adjusted by age, sex and hypertension | |
|-------------------|------------|---|-------------------------|---|--------------------------|---|
|                   | OR (95% CI) | p  | OR (95% CI) | p  | OR (95% CI) | p  |
| **IGFBP7**        |            |    |            |    |            |    |
| Atrial fibrillation | 8.87  | 3.71–21.20 | 9.1 x 10⁻⁷ | 6.70 | 2.59–17.32 | 8.8 x 10⁻⁵ | 6.79 | 2.62–17.60 | 8.0 x 10⁻⁵ |
| E/e'              | 0.23      | 0.13–0.41 | 7.0 x 10⁻⁷ | 0.33 | 0.17–0.64 | 0.001 | 0.34 | 0.18–0.64 | 0.001 |
| Enlarged LAA       | 21.64     | 5.77–81.21 | 5.0 x 10⁻⁶  | 12.68 | 3.01–53.42 | 0.001 | 12.72 | 3.01–53.86 | 0.001 |
| LVH               | 4.96      | 2.54–9.69 | 3.0 x 10⁻⁶  | 4.67 | 2.24–9.73 | 3.9 x 10⁻⁵ | 4.51 | 2.15–9.48 | 6.8 x 10⁻⁵ |
| MFS               | 4.24      | 2.21–8.16 | 1.5 x 10⁻⁵  | 2.52 | 1.25–5.07 | 0.010 | 2.44 | 1.21–4.93 | 0.013 |
| **GDF-15**         |            |    |            |    |            |    |
| Atrial fibrillation | 2.79      | 2.01–3.87 | 7.2 x 10⁻¹⁰ | 2.52 | 1.77–3.57 | 2.7 x 10⁻⁷ | 2.51 | 1.77–3.57 | 3.0 x 10⁻⁷ |
| E/e'              | 0.62      | 0.50–0.78 | 2.3 x 10⁻⁵  | 0.72 | 0.56–0.91 | 0.006 | 0.71 | 0.56–0.90 | 0.004 |
| Enlarged LAA       | 2.45      | 1.45–4.13 | 0.001       | 1.67 | 0.90–3.07 | 0.103 | 1.70 | 0.92–3.14 | 0.091 |
| LVH               | 1.70      | 1.33–2.19 | 3.4 x 10⁻⁵  | 1.67 | 1.27–2.19 | 2.8 x 10⁻⁴ | 1.72 | 1.30–2.27 | 1.4 x 10⁻⁴ |
| MFS               | 2.18      | 1.70–2.81 | 1.2 x 10⁻⁹  | 1.85 | 1.41–2.42 | 8.0 x 10⁻⁶ | 1.89 | 1.44–2.48 | 4.0 x 10⁻⁶ |
| **P1NP**           |            |    |            |    |            |    |
| Atrial fibrillation | 1.27      | 0.89–1.82 | 0.189       | 1.19 | 0.83–1.72 | 0.337 | 1.20 | 0.83–1.72 | 0.334 |
| E/e'              | 0.88      | 0.72–1.09 | 0.238       | 0.99 | 0.81–1.24 | 0.994 | 1.00 | 0.81–1.25 | 0.977 |
| Enlarged LAA       | 1.44      | 0.80–2.57 | 0.222       | 1.32 | 0.74–2.36 | 0.354 | 1.31 | 0.73–2.34 | 0.369 |
| LVH               | 1.12      | 0.87–1.44 | 0.376       | 0.96 | 0.74–1.25 | 0.777 | 0.96 | 0.74–1.25 | 0.761 |
| MFS               | 0.92      | 0.72–1.17 | 0.494       | 0.90 | 0.71–1.15 | 0.416 | 0.91 | 0.71–1.16 | 0.445 |

Logistic univariate and multivariate regression analyses with cardiac phenotype (dependent) and Ln-transformed IGFBP7, GDF-15 and P1NP
E/e' > 8 vs ≤ = 8; GDF-15, growth differentiation factor-15; IGFBP7, insulin growth factor binding protein; P1NP, amino-terminal propeptide of type I procollagen. LAA, left atrial area, enlarged if > 20; LVH, left ventricular hypertrophy defined as LV mass/BSA > 95 g/m² for women and > 115 g/m² for men; MFS, midwall circumference fraction shortening, reduced if MFS < 15%
Fig. 1  Kaplan–Meier curves for: all-cause and cardiovascular mortality, all-cause-, cardiovascular- and heart failure hospitalization split by tertiles of IGFBP7 and GDF-15. $p$ value for log-rank test for the comparison of Kaplan–Meier estimates. Blue—lowest tertile, red- middle tertile, green—highest tertile
### Table 5 Results of Cox proportional hazard regression models

| N       | All-cause mortality | CV mortality | Hospitalization | CV hospitalization |
|---------|---------------------|--------------|-----------------|-------------------|
|         | HR[95CI] | p      | HR[95CI] | p      | HR[95CI] | p      | HR[95CI] | p      |
| **IGFBP7** |          |        |          |        |          |        |          |        |
| Univariate | 1634    | 17.17  | 1.1 × 10−40 | [1.131–26.05] | 31.7  | 9.8 × 10−20 | [15.06–66.87] | 2.31 | 7.5 × 10−7 | [1.66–3.21] | 4.48 | 2.5 × 10−11 | [2.89–6.96] |
| Multivariable | 1486    | 5.20   | 2.0 × 10−7 | [2.79–9.68] | 7.73  | 0.001 | [2.28–26.26] | 1.50 | 0.057 | [0.99–2.28] | 2.26 | 0.006 | [1.27–4.01] |
| Multivariable + echo | 809    | 4.25   | 0.001 | [1.81–9.99] | 2.52  | 0.279 | [0.47–13.39] | 1.11 | 0.733 | [0.61–2.01] | 1.65 | 0.204 | [0.76–3.57] |
| Multivariable + biomarkers | 1486    | 2.13   | 0.029 | [1.08–4.22] | 1.97  | 0.329 | [0.51–7.66] | 0.94 | 0.794 | [0.60–1.48] | 1.04 | 0.911 | [0.55–1.94] |
| **GDF-15** |          |        |          |        |          |        |          |        |
| Univariate | 1705    | 3.44   | 4.0 × 10−16 | [2.95–4.02] | 3.96  | 6.0 × 10−19 | [2.92–5.36] | 1.60 | 3.0 × 10−14 | [1.42–1.80] | 1.91 | 2.3 × 10−15 | [1.63–2.24] |
| Multivariable | 1621    | 2.58   | 2.5 × 10−18 | [2.09–3.20] | 2.84  | 4.0 × 10−6 | [1.82–4.43] | 1.32 | 3.3 × 10−4 | [1.13–1.53] | 1.50 | 1.2 × 10−4 | [1.21–1.84] |
| Multivariable + echo | 843    | 2.50   | 1.9 × 10−8 | [1.82–3.44] | 1.89  | 0.067 | [0.96–3.73] | 1.42 | 0.001 | [1.15–1.77] | 1.44 | 0.011 | [1.09–1.92] |
| Multivariable + biomarkers | 1621    | 2.03   | 1.5 × 10−9 | [1.62–2.56] | 1.75  | 0.028 | [1.06–2.88] | 1.17 | 0.059 | [0.99–1.37] | 1.22 | 0.079 | [0.98–1.53] |

Cox proportional hazard models for all-cause mortality or hospital admission for cardiovascular reason. HR [95%CI] for Ln-transformed concentration of the biomarker. For IGFBP7 the multivariable regression analysis was corrected for age, sex, eGFR, diabetes, smoking, dyslipidaemia, MI, AF, heart failure as identified in Table 1. For GDF-15 the multivariable regression analysis was corrected for age, sex, eGFR, diabetes, smoking, dyslipidaemia, angina, MI, AF and COPD, as identified in Table 2. Echo: included MFS and enlarged left atrial area in the regression analyses.

Biomarkers: included log-transformed hsTnT and log-transformed NTproBNP in the regression analysis.

### Abbreviations

AF: Atrial fibrillation; AHA/ACC: American Heart Association/American College of Cardiologists; BSA: Body surface area; COPD: Chronic obstructive pulmonary disease; CV: Cardiovascular; EDTA: Ethylenediamine tetraacetic acid tripotassium salt; EF: Ejection fraction; eGFR: Estimated glomerular filtration rate; FU: Follow-up; GDF15: Growth differentiation factor-15; HF: Heart failure; HR: Hazard ratio; hs-cTnT: High sensitive cardiac Troponin-T; IGFBP7: Insulin-like growth factor-binding protein-7; LAA: Left atrial area; LV: Left ventricle; LVH: Left ventricular hypertrophy; MFS: Midwall circumference shortening; MI: Myocardial infarct; NT-proBNP: N-terminal brain natriuretic peptide; P1NP: Propeptide of type I procollagen; PICP: Procollagen type I carboxy-terminal propeptide; PIIINP: Amino-terminal propeptide type III procollagen; PREDICTOR: Valutazione della PREvalenza di Disfunzione Cardiaca asinTOmatica e di scompenso caRdiaco.

### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12872-021-02138-8.

Additional file 1. Supplemental material.

Acknowledgements

The PREDICTOR Study Group: A. Boccanielli, G. Cacciatore, G.F. Mureddu, V Rizziello (S. Giovanni-Addolorata Hospital, Roma); N. Agabiti, G. Cesaroni, F Forastiere, C.A. Perucci, M. Davoli (Department of Epidemiology, ASL Roma 1,Roma); F. Colivicchi, M. Santini (S. Filippo Neri Hospital, Roma); R. Latini (Mario Negri Institute, Milano); M. Ugucioni (A. Alesini Hospital,Roma); M. Iacomelli, M. Di Gennaro (S. Paolo Hospital, Civitavecchia); F. Quandaltri, V. Panicia (Umberto I Hospital, Frosinone); F. Ammirati, R. Donati, F. Fiaschetti (GB Grassi Hospital, Ostia); G. Barbato, T.A. Gaspardone (S. Eugenio Hospital, Roma); G. Vitaliani, F. Catalano (S. Giacomo Hospital, Roma); A. Achilli (Belcolle Hospital Viterbo).

Authors’ contributions

All authors adhere to the four ICMJE authorship criteria and had full access to the data in the study and take complete responsibility for the integrity and accuracy of the data analysis. RL and SM conceived the idea and designed the study. RL, JMTAM, MM and LIS contributed to the interpretation of the results. The manuscript was drafted by RL with the help of JMTAM and GC and then shared with all authors for critical revision. All authors have read and approved the final manuscript.

Funding

The PREDICTOR study was funded by Takeda Italia Farmaceutici S.p.A, Rome, Italy; the funders had no role in the concept or design of the study, or in the data reporting.

Availability of data and materials

The data are stored at the Department of Epidemiology-Regional Health Service in Rome, at the S. Giovanni-Addolorata Hospital in Rome, and at the Mario Negri Institute for Pharmacological Research in Milan. For privacy policies of the PREDICTOR study, data sharing is not possible.
Declarations

Ethics approval and consent to participate
Ethics approval was obtained from the S. Giovanni-Addolorata Hospital Ethics Committee (Prot N. S.177/12 on April 5, 2007). Each participant provided a written informed consent.

Consent for publication
Not applicable.

Competing interests
UHWT, PMK and SM are employees at Roche Diagnostics. Roche diagnostics had no role in data analysis, but carefully revised the manuscript and contributed to the interpretation of findings of this study. JMTAM, GC, GFM, AB, MLOF, LKJ, et al. BMJ. 2009;345(b):1–8. Competing interests Not applicable.

Author details
1. Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. 2. Department of Epidemiology, Lazio Regional Health Service, ASL Roma 1, Rome, Italy. 3. Department of Cardiovascular Diseases, S Giovanni-Addolorata Hospital, Rome, Italy. 4. Casa di Cura Quisisiana, Rome, Italy. 5. Roche Diagnostics GmbH, Penzberg, Germany. 6. Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. 7. Centro Medico Specialistico UniSalus, Milan, Italy. 8. Roche Diagnostics International, Rotkreuz, Switzerland.

Received: 1 April 2021 Accepted: 24 June 2021

Published online: 03 July 2021

References
1. Biernacka A, Frangogiannis NG. Aging and cardiac fibrosis. Aging Dis. 2011;2(2):158–73.
2. Chugh S, Ouzounian M, Lu Z, Mohamed S, Li W, Bousette N, et al. Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics. 2013;13(15):2324–34.
3. Gandhi PU, Gaggin HK, Redfield MM, Chen HH, Stevens SR, Anstrom KJ, et al. Insulin-like growth factor-binding protein-7 as a biomarker of diastolic dysfunction and functional capacity in heart failure with preserved ejection fraction: results from the RELAX trial. JACC Heart Fail. 2016;4(11):860–9.
4. Kalayci A, Peacock WF, Nagurney JT, Hollander JE, Levy PD, Singer AJ, et al. Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure. ESC Heart Fail. 2020.
5. Ibrahimi NE, Afflato M, Chen-Tournoux A, Christenson RH, Gaggin HK, Hollander JE, et al. Diagnostic and prognostic utilities of insulin-like growth factor binding protein-7 in patients with dyspnea. JACC Heart Fail. 2020;8(9):415–22.
6. Januzzi JL, Packard M, Caggert B, Liu J, Shah AM, Zile MR, et al. IGFBP7 (insulin-like growth factor-binding protein-7) and nephrilysin inhibition in patients with heart failure. Circ Fail Heart. 2018;11(10):e005133.
7. Blum S, Aeschbacher S, Meyre P, Kühne M, Rodondi N, Beer JH, et al. Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. Heart Rhythm. 2020.
8. George M, Jena A, Srivatsan V, Muthukumar R, Dhandapani V. GDF 15—a novel biomarker in the offing for heart failure. Curr Cardiol Rev. 2016;12(1):37–46.
9. Zile MR, O’Meara E, Caggert B, Prescott MF, Solomon SD, Swedberg K, et al. Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol. 2019;73(7):795–806.
10. Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem. 2017;63(1):40–51.
11. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Growth differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation. 2011;123(19):2101–10.
12. Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, et al. Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RE-LY trial. J Am Heart Assoc. 2019;8(2):e010107.
13. Garnero P, Vergnaud P, Hoye N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem. 2006;54(1):188–96.
14. Dupuy AM, Kuster N, Curinier C, Huet F, Plaweski M, Salecic K, et al. Exploring collagen remodeling and regulation as prognostic biomarkers in stable heart failure. Clin Chim Acta. 2019;490:167–71.
15. Mureddu GF, Agabiti N, Rizzello V, Forastiere F, Latini R, Cesaroni G, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail. 2012;14(7):718–29.
16. Cesaroni G, Agabiti N, Forastiere F, Perucci CA. Socioeconomic differences in stroke incidence and prognosis under a universal healthcare system. Stroke. 2009;40(8):2812–9.
17. Kirchmayer U, Di Martino M, Agabiti N, Bauleo L, Fusco D, Bellieu U, et al. Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: a nested case–control study in Italy. Pharmacoeconom Drug Saf. 2013;22(6):649–57.
18. Huang HD, Turner M, Lederle F. Abstract 320: Accuracy of ICD-9 Codes for Identifying Acute Heart Failure Hospitalizations. Circul Cardiovasc Qual Outcomes. 2015;8(suppl_2):A320–A320.
19. Paulus WJ, Tschöpe C, Sanderson JE, Russoni C, Flachskampf FA, Radermakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction from the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539–50.
20. Nagueth SF, Smiseth OA, Appleton CP, Byrd BF, Dohanish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.
21. López B, González A, Querejeta R, Zubillaga E, Larman M, Díez J. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail. 2015;17(4):385–92.
22. Gandhi PU, Gaggin HK, Sheffel AD, Belcher AM, Weiner RB, Baggish AL, et al. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic dysfunction? Am J Cardiol. 2014;114(10):1543–9.
23. Banoso MC, Kramer F, Greene SJ, Scheyer D, Köhler T, Karoff M, et al. Serum insulin-like growth factor-1 and its binding protein-2: potential novel biomarkers for heart failure with preserved ejection fraction. JACC Cardiovasc Disord. 2016;16(1):1199.
24. Jørgensen NR, Mallehave LT, Hansen YB, Quarton N, Lyloff L, Linneberg A. Comparison of two automated assays of BTM (CTX and PINP) and reference intervals in a Danish population. Osteoporos Int. 2017;28(7):2103–13.
25. Bao X, Born Y, Muhammad JF, Nilsson J, Lind L, Melander O, et al. Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö Diet and Cancer-Cardiovascular Cohort. Diabetologia. 2019;62(1):78–86.
26. Fuglsang-Nielsen R, Rakvaag E, Vestergaard P, Hartmann B, Holst JJ, Hermansen K, et al. Consumption of nutrients and insulin resistance suppress markers of bone turnover in subjects with abdominal obesity. Bone. 2020;133:115230.
27. An Y, Liu S, Wang W, Dong H, Zhao W, Ke J, et al. Low serum levels of bone turnover markers are associated with the presence and severity of diabetic retinopathy in patients with type 2 diabetes mellitus. J Diabetes. 2020.
28. Hunt HB, Miller NA, Hemmerling KJ, Koga M, Lopez KA, Taylor EA, et al. Bone tissue composition in post-menopausal women varies with glycemic control from normal glucose tolerance to type 2 diabetes mellitus. J Bone Miner Res. 2020.
29. Ho JE, Mahajan A, Chen M-H, Larson MG, McCabe EL, Ghorbani A, et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem. 2012;58(11):1582–91.
30. Andersson C, Enserro D, Sullivan L, Wang TJ, Januzzi JL, Benjamin EJ, et al. Relations of circulating GDF-15, soluble ST2, and troponin-I.
concentrations with vascular function in the community: the Framingham Heart Study. Atherosclerosis. 2016;248:245–51.
31. Lind L, Wallentin L, Kempt T, Tapken H, Quint A, Lindahl B, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J. 2009;30(19):2346–53.
32. Rohatgi A, Patel P, Das SR, Ayers CR, Khera A, Martinez-Rumayor A, et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. Clin Chem. 2012;58(1):172–82.
33. Sanders-van Wijk Sandra, Tromp Jasper, Beussink-Nelson Lauren, Hage Camilla, Svedlund Sara, Saraste Antti, et al. Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure with Preserved Ejection Fraction: Results from the PROMIS-HFpEF Study. Circulation [Internet]. [cited 2020 Oct 27];0(0). https://doi.org/10.1161/CIRCULATIONNAHA.120.045810
34. Wallentin L, Zethelius B, Berglund L, Eggers KM, Lind L, Lindahl B, et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS ONE. 2013;8(12):e78797.
35. Doerstling S, Hedberg P, Ohvik J, Leppert J, Henriksen E. Growth differentiation factor 15 in a community-based sample: age-dependent reference limits and prognostic impact. Ups J Med Sci. 2018;123(2):86–93.
36. Xanthakis V, Larson MG, Wollert KC, Aragam J, Cheng S, Ho J, Cogliani E, Levy D, Colucci WS, Michael Felker G, Benjamin EJ, Januzzi JL, Wang TJ, Vasan RS. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc. 2013;2(6):e000399. https://doi.org/10.1161/JAHA.113.000399. PMID: 24200688; PMCID: PMC3886765.
37. Masson S, Latini R, Mureddu GF, Agabiti N, Miceli M, Cesaroni G, Forastiere F, Wienshues-Thelen UH, Block D, Zauugg C, Vago T, Boccanelli A. PREDICTOR study. High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals. J Intern Med. 2013;273(3):306–17. https://doi.org/10.1111/joim.12023.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.